CLINICAL_TRIALS
trial_result
· 2013-05-07
Clinical Trial Update: A Phase II, Dose Ranging Study Of CP-690,550 Eye Drops In Patients With Dry Eye Disease [Phase 2]
Summary
Pfizer completed a Phase II dose-ranging study of CP-690,550 eye drops for dry eye disease, with results posted in 2013.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Dry Eye Syndromes | Phase 2 | Status: COMPLETED | Results posted: 2013-05-07